28-12-19, Croix de guerre et Légion d'honneur à [la ville de] Lens [le président Poincaré et les officiels en voiture parmi les ruines] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57368

28-12-19, Croix de guerre et Légion d'honneur à [la ville de] Lens [le président Poincaré et les officiels dans la ville en ruines] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57366

Verdun, 16/2/20, M. Poincaré reçu par Mgr Ginisty [porche de la cathédrale] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58037

18/2/20, transmission des pouvoirs, réception des quatre présidents à l'Hôtel de ville [MM. Loubet, Deschanel, Poincaré, Fallières] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58104

17-1-20, Congrès de Versailles, MM. Ribot [Alexandre] et Selves [Justin de] [sénateurs] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57693

28-1-20, [voyage présidentiel de M. Raymond Poincaré] devant la mairie de Nieuport : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57781

[28-12-19, voyage présidentiel pour la remise de la] Croix de guerre et [de la] Légion d'honneur à [la ville de] Béthune [ruines] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57373

La voix de M. Raymond Poincaré, Président de la République française : discours prononcé le 14 juillet 1915

[Discours. 1915-07-14]

28/12/19, voyage présidentiel à Arras [la foule devant la tribune présidentielle] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57357

G-1 Appeal Activity In The Public Assistance Programs, October 2004

G-1 Appeal Activity In The Public Assistance Programs

Long-term ex vivo expansion of human fetal liver primitive haematopoietic progenitor cells in stroma-free cultures

Successful expansion of haematopoietic cells in ex vivo cultures will have important applications in transplantation, gene therapy, immunotherapy and potentially also in the production of non-haematopoietic cell types. Haematopoietic stem cells (HSC), with their capacity to both self-renew and differentiate into all blood lineages, represent the ideal target for expansion protocols. However, human HSC are rare, poorly characterized phenotypically and genotypically, and difficult to test functionally. Defining optimal culture parameters for ex vivo expansion has been a major challenge. We devised a simple and reproducible stroma-free liquid culture system enabling long-term expansion of putative haematopoietic progenitors contained within frozen human fetal liver (FL) crude cell suspensions. Starting from a small number of total nucleated cells, a massive haematopoietic cell expansion, reaching > 1013-fold the input cell number after approximately 300 d of culture, was consistently achieved. Cells with a primitive phenotype were present throughout the culture and also underwent a continuous expansion. Moreover, the capacity for multilineage lymphomyeloid differentiation, as well as the recloning capacity of primitive myeloid progenitors, was maintained in culture. With its better proliferative potential as compared with adult sources, FL represents a promising alternative source of HSC and the culture system described here should be useful for clinical applications.

A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety.

AIMS: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). METHODS: This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women. They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment. Clinical cure based on Amsel's criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety. RESULTS: Cure rates with DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 78.4%, C2: 77.6%). Thus, the treatment with DQC had equal efficacy as CLM cream. A trend to less common post-treatment VVC in the DQC-treated women was observed (DQC: 2.5%, CLM: 7.7%; p = 0.06). Both treatments were well tolerated with no serious adverse events occurring. CONCLUSION: Vaginal DQC has been shown to be equally effective as CLM cream, to be well tolerated with no systemic safety concerns, and is therefore a valid alternative therapy for women with BV [ClinicalTrials.gov, Med380104, NCT01125410].